Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab with TP Induction in LA SCCHN
NCT05376553Phase 1Enrolling by invitation
- Start
- Jul 2022
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of cemiplimab in squamous cell carcinoma of the head and neck (HNSCC) (2 cohorts). Primary endpoint: Dose-limiting toxicity at 3 weeks. Started Jul 2022; status: enrolling by invitation.
02
Drugs
cemiplimab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05376553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376553.